Novartis AG (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 143   

Articles published

NVS 101.31 +0.91 (0.91%)
price chart
Novartis AG (ADR) Partners With Aduro Biotech With A $750 Million Deal
Novartis AG (ADR) (NYSE:NVS) has announced a deal with cancer immunotherapy company, Aduro Biotech, Inc., in which both the companies will partner to research and manufacture treatments for cancer.
Gender Discrimination Lawsuit Filed Against Novartis AG (ADR)(NYSE:NVS)
It was filed by two individuals who had formerly been the employees of Novartis AG (ADR) (NYSE:NVS). They claimed that the company has acquired a unit in the year 2010 worth $51 billion, namely Alcon laboratories Ltd.
Bristol-Myers Squibb Co, Sanofi SA (ADR), and Novartis AG (ADR) Lead 2015 ...
Bristol-Myers Squibb Co (NYSE:BMY), Sanofi SA (ADR)(NYSE:SNY), and Novartis AG's (ADR)(NYSE:NVS) will be 2015's most valuable new drug launches, says a report published on Monday.
New Blockbuster Drugs Expected From Sanofi SA (ADR) (NYSE:SNY), Bristol ...  NYSE Post
Asset Swaps Of Novartis AG (ADR) (NYSE:NVS) and GlaxoSmithKline plc (ADR ...
An Announcement regarding the completion of a range of asset swaps was made concerning two significant companies, GlaxoSmithKline plc (ADR) (NYSE:GSK) and Novartis AG (ADR) (NYSE:NVS). These asset swaps tended to be a bit complex and were ...
GlaxoSmithKline plc (ADR) And Novartis AG (ADR) Complete Three-Part Deal ...  Bidness ETC
GlaxoSmithKline plc (ADR) (NYSE:GSK) Update: GlaxoSmithKline sees Novartis ...  Ashburn Daily
Steady Healthcare Stocks: Novartis AG (ADR) (NVS), Sagent Pharmaceuticals ...
Manhattan, NY- March 30, 2015 - (Techsonian) - Novartis AG (ADR) (NVS) develops, manufactures, and markets a range of healthcare products worldwide.
Amgen, Inc. Petition Against Novartis AG (ADR) Denied By Court- Biosimilar ...
A US judge has struck down Amgen Inc.'s (NYSE:AMGN) petition to prevent Novartis AG ADR (NYSE:NVS) launching a biosimilar version of its blockbuster neutropenia treatment drug, Neupogen, in the US.
Novartis AG (ADR) Cosentyx More Effective Than Johnson & Johnson Stelara
Novartis AG (ADR) (NYSE:NVS) announced yesterday that results from a late-stage clinical trial demonstrated that Cosentyx, its new treatment for psoriasis, outperformed Johnson & Johnson's (NYSE:JNJ) blockbuster drug Stelara.
Novartis AG ADR (NVS): New Analyst Report from Zacks Equity Research ...
We are impressed by Novartis' efforts to realign its portfolio in order to focus on its core portfolio of pharmaceuticals, eye care and generics. The agreement to acquire oncology products from Glaxo will further broaden Novartis' portfolio, enable it ...
Related articles »  
Arrowhead Research Corp To Acquire Novartis AG (ADR) RNAi Assets
Arrowhead Research Corp (NASDAQ:ARWR), which develops targeted RNAi therapeutics, announced Thursday that it will acquire Novartis AG's (ADR) (NYSE:NVS) RNAi research and development portfolio and other assets in efforts to strengthen its work in ...
Small Cap Stocks Under Consideration - Arrowhead Research (ARWR),Neustar ...  Investor Wired
Zarxio, Novartis AG (ADR) (NYSE:NVS) Biosimilar Drug Gets Approved by FDA
Zarxio, the bio similar drug manufactured by Novartis AG (ADR) (NYSE:NVS) got approved by the US Food and Drug Administration, last Friday.
Amgen, Inc. Plans For Biosimilar Launches  Bidness ETC